Lacey E. Dobrolecki

Department of Molecular and Cellular Biology, Baylor College of Medicine

Affiliated withBaylor College of Medicine

Research Area

Cancer Research

Biography

Lacey E. Dobrolecki has not added Biography.
If you are Lacey E. Dobrolecki and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 15	2020

Other Publications

Article	Year
Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PloS one\| PubMed ID: 22879872	2012
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer research\| PubMed ID: 23737486	2013
Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy. Journal of biomolecular screening\| PubMed ID: 24525869	2014
Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene\| PubMed ID: 24681959	2015
A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer. Molecular pharmacology\| PubMed ID: 25480843	2015
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast cancer research : BCR\| PubMed ID: 25572662	2015
Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells. Breast cancer research : BCR\| PubMed ID: 26757880	2016
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nature cell biology\| PubMed ID: 27183469	2016
Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer metastasis reviews\| PubMed ID: 28025748	2016
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature\| PubMed ID: 28371798	2017
Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta biomaterialia\| PubMed ID: 28465075	2017
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. The Journal of clinical investigation\| PubMed ID: 29480818	2018
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nature medicine\| PubMed ID: 29578538	2018
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nature communications\| PubMed ID: 30232459	2018
C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes. Oncogene\| PubMed ID: 30262865	2019
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC cancer\| PubMed ID: 30871481	2019
Chromosome 12p Amplification in Triple-Negative/Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer research\| PubMed ID: 31213465	2019
The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular cancer research : MCR\| PubMed ID: 31320385	2019
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. Journal of clinical medicine\| PubMed ID: 31652963	2019